Rhumbline Advisers Acquires 8,987 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

Rhumbline Advisers lifted its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 8.2% in the second quarter, Holdings Channel.com reports. The fund owned 118,526 shares of the biotechnology company’s stock after purchasing an additional 8,987 shares during the quarter. Rhumbline Advisers’ holdings in REGENXBIO were worth $1,387,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Vanguard Group Inc. lifted its holdings in shares of REGENXBIO by 9.8% during the 1st quarter. Vanguard Group Inc. now owns 4,876,881 shares of the biotechnology company’s stock worth $102,756,000 after acquiring an additional 436,043 shares during the period. Redmile Group LLC lifted its holdings in shares of REGENXBIO by 21.0% during the 1st quarter. Redmile Group LLC now owns 4,551,556 shares of the biotechnology company’s stock worth $95,901,000 after acquiring an additional 790,866 shares during the period. Dimensional Fund Advisors LP lifted its holdings in REGENXBIO by 2.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,226,957 shares of the biotechnology company’s stock valued at $22,025,000 after purchasing an additional 34,385 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in REGENXBIO by 258.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 816,384 shares of the biotechnology company’s stock valued at $9,552,000 after purchasing an additional 588,773 shares during the last quarter. Finally, Perceptive Advisors LLC bought a new position in REGENXBIO during the 4th quarter valued at about $6,146,000. 88.08% of the stock is owned by institutional investors.

Insider Transactions at REGENXBIO

In other news, Director Argeris N. Karabelas sold 10,000 shares of REGENXBIO stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $11.27, for a total transaction of $112,700.00. Following the completion of the sale, the director now owns 11,286 shares in the company, valued at approximately $127,193.22. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, Director Argeris N. Karabelas sold 10,000 shares of REGENXBIO stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $11.27, for a total transaction of $112,700.00. Following the completion of the sale, the director now owns 11,286 shares in the company, valued at approximately $127,193.22. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Kenneth T. Mills sold 2,210 shares of REGENXBIO stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $13.77, for a total transaction of $30,431.70. Following the sale, the director now owns 408,035 shares of the company’s stock, valued at approximately $5,618,641.95. The disclosure for this sale can be found here. Insiders sold a total of 65,279 shares of company stock worth $875,634 in the last quarter. 13.13% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Barclays cut their price target on shares of REGENXBIO from $55.00 to $50.00 and set an “overweight” rating for the company in a report on Monday, August 5th. The Goldman Sachs Group assumed coverage on shares of REGENXBIO in a report on Friday, June 7th. They set a “buy” rating and a $38.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $39.00 price target on shares of REGENXBIO in a report on Wednesday, September 4th. Finally, StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, REGENXBIO has a consensus rating of “Moderate Buy” and an average target price of $37.91.

REGENXBIO Trading Down 6.5 %

RGNX opened at $11.69 on Friday. The stock has a market capitalization of $575.80 million, a PE ratio of -1.99 and a beta of 1.22. REGENXBIO Inc. has a 1-year low of $10.49 and a 1-year high of $28.80. The firm has a 50-day moving average price of $12.52 and a two-hundred day moving average price of $15.00.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($1.05) earnings per share for the quarter, beating the consensus estimate of ($1.29) by $0.24. REGENXBIO had a negative net margin of 270.74% and a negative return on equity of 68.21%. The firm had revenue of $22.30 million during the quarter, compared to analysts’ expectations of $22.97 million. During the same quarter last year, the company posted ($1.66) EPS. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. On average, research analysts predict that REGENXBIO Inc. will post -4.66 EPS for the current year.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.